N/A
Completed N=447
Multidisciplinary Support Program in Chronic Hepatitis C
Hepatitis C, Chronic
Source: ClinicalTrials.gov NCT01850745 ↗
Enrolled (actual)
447
Serious AEs
1.3%
Results posted
Jul 2018
Primary outcomePrimary: Adherence to Treatment — 116; 155; 124 participants
Summary
Adherence to antiviral treatment in chronic hepatitis C (CHC) is an important factor to achieve sustained virological response (SVR). The aim of our study is to evaluate the efficacy of a multidisciplinary support program (MSP) in adherence to and efficacy of pegylated interferon alfa-2a and ribavirin compared to the conventional approach. We assessed 447 patients with CHC receiving antiviral treatment distributed into 3 groups: control group (recruited 2002-2004, n= 147), MSP-pilot group (recruited 2005-2006, n=131), and MSP-validation group (recruited 2007-2009, n=169).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Adherence to Treatment |
116; 155; 124 | — |
| SECONDARY Efficacy of Treatment Measured by Sustained Virological Response |
— | — |
Eligibility Criteria
Inclusion Criteria
- Patients with chronic hepatitis C eligible to receive antiviral treatment.
Exclusion Criteria
- Patients who had undergone previous antiviral treatment, those with human immunodeficiency virus (HIV) or hepatitis B virus (HBV) co-infection, and individuals included in other treatment protocols.
Data sourced from ClinicalTrials.gov (NCT01850745). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.